TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12/2/09 15:37 | 11/30/09 | ORXE | Ore Pharmaceutical Holdings Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Gabrielson Mark J | MD | DO | CEO | P | 1 | 0.6200 | 0 | 2 | 17 | 14 | D | ||||||||||||||
11/23/09 11:47 | 11/17/09 | ORXE | Ore Pharmaceutical Holdings Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Gabrielson Mark J | MD | DO | CEO | P.m | 3 | 0.6299 | 0 | 4 | 67 | 10 | D | ||||||||||||||
8/28/09 16:19 | 8/27/09 | ORXE | Ore Pharmaceuticals Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Gabrielson Mark J | MD | DO | CEO | P | 1 | 0.5800 | 0 | 2 | 50 | 6 | D | ||||||||||||||
8/19/09 13:44 | 8/18/09 | ORXE | Ore Pharmaceuticals Inc. | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Gabrielson Mark J | MD | DO | CEO | P | 1 | 0.5950 | 0 | 2 | 100 | 4 | D | ||||||||||||||
11/29/07 12:21 | 11/28/07 | GLGC | Gene Logic Inc | DE | Health | Diagn | In Vitro & In Vivo Diagnostic | Gabrielson Mark J | MD | D | P | 9 | 0.9374 | 0 | 10 | New | 10 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |